Published accounts described how a new drug targeting the KRAS mutation driving most pancreatic cancers shows remarkable results in clinical trials nearly doubling patient survival time.
Available records indicate a new drug targeting the KRAS mutation driving most pancreatic cancers shows remarkable results in clinical trials nearly doubling patient survival time.
Published accounts described how a new drug targeting the KRAS mutation driving most pancreatic cancers shows remarkable results in clinical trials nearly doubling patient survival time.
Reporting on June 4, 2026, noted that a new drug targeting the KRAS mutation driving most pancreatic cancers shows remarkable results in clinical trials nearly doubling patient survival time.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/